Advertisement

Drug Safety

, Volume 29, Issue 10, pp 944–944 | Cite as

ABSTRACTS: ISoP Annual Conference ‘Joining Forces for Managing Risks’ Liège, Belgium 11–13 October, 2006

  • T. Roisin
  • A. Van Ermen
  • A. Rogiers
Abstracts

Keywords

Verapamil Diltiazem Dioxin Hypokalemia Cholinesterase Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Répertoire Commenté des Médicaments 2006/Gecommentarieerd Geneesmiddelenrepertorium 2006, edited by the Belgian Center for Pharmacotherapeutic Information (CBIP/BCFI)Google Scholar
  2. 2.
    Leentjes AFG, Kragten JA. Totaal atrioventriculair blok tijdens behandeling met galantamine. Ned Tijdschr Geneesk 2006; 150: 563–6Google Scholar
  3. 3.
    Anonymous. Maladie d’Alzheimer: gare aux interactions avec les anticholinestérasiques. La Revue Prescrire 2006; 26: 111–5Google Scholar
  4. 4.
    Anonymous. Effect indésirables cardiaques des inhibiteurs des cholinestérases/Cardiale ongewenste effecten van cholinesterase-inhibitoren. Folia Pharmacotherapeutica 2006; 33:54 (via http://www.cbip.be/http://www.bcfi.be)Google Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • T. Roisin
    • 1
  • A. Van Ermen
    • 2
  • A. Rogiers
    • 3
  1. 1.Vigilance departmentDirectorate-General for Medicinal Products (DGMP) Federal Public Service Health, Food Chain Safety and EnvironmentBrusselsBelgium
  2. 2.Belgian Centre for Pharmacotherapeutic Information (BCFI/CBIP)GentBelgium
  3. 3.Registration DepartmentDirectorate-General for Medicinal Products (DGMP), Federal Public Service Health, Food Chain Safety and EnvironmentBrusselsBelgium

Personalised recommendations